AG
SYRE icon

Algert Global’s Spyre Therapeutics SYRE Stock Holding History

Algert Global’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
+16,460
New +$1.2M 0.02% 923
2022
Q2 		– Sell
-2,278
Closed -$131K – 1379
2022
Q1 		$131K Buy
2,278
+981
+76% +$82.4K 0.01% 1085
2021
Q4 		$154K Sell
1,297
-175
-12% -$27.6K 0.02% 888
2021
Q3 		$293K Sell
1,472
-188
-11% -$32.9K 0.04% 768
2021
Q2 		$289K Sell
1,660
-1,013
-38% -$184K 0.1% 293
2021
Q1 		$529K Sell
2,673
-1,475
-36% -$283K 0.17% 197
2020
Q4 		$816K Sell
4,148
-174
-4% -$36.1K 0.23% 156
2020
Q3 		$766K Buy
+4,322
New +$800K 0.24% 149
2019
Q4 		– Sell
-936
Closed -$180K – 435
2019
Q3 		$180K Buy
936
+54
+6% +$10.5K 0.07% 290
2019
Q2 		$151K Buy
882
+148
+20% +$25.6K 0.06% 300
2019
Q1 		$148K Sell
734
-293
-29% -$61.1K 0.08% 263
2018
Q4 		$192K Buy
+1,027
New +$218K 0.05% 336

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Algert Global's SYRE Position: Q2 2026 in Review

Algert Global opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 16,460 shares worth $1.46M. The stake represents 0.02% of the portfolio and ranks #923 among its holdings. This is a return to the name: Algert Global previously reported a position in SYRE as recently as Q1 2022.

Algert Global first reported a position in SYRE in Q4 2018 and has held it in 12 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Algert Global held 16,460 shares of Spyre Therapeutics worth $1.46M as of Q2 2026.
  • Spyre Therapeutics was a new Algert Global position in Q2 2026.
  • Spyre Therapeutics made up 0.02% of Algert Global's portfolio in Q2 2026, its #923 holding.
  • Algert Global first reported a position in Spyre Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.